Eribulin rapidly reduces the aggressiveness of second primary breast cancer: A case report

Isacco Falco, Silvia Stragliotto

Research output: Contribution to journalArticlepeer-review

Abstract

The cytotoxic agent, eribulin represents a new standard of care in the treatment of heavily pretreated metastatic breast cancer patients. Here, we describe our experience with eribulin in a patient with a controlled primary breast cancer, who showed an aggressive recurrence of the primary tumor, including metastatic disease. Treatment management of the second primary tumor included six lines of chemotherapy and three lines of hormonal therapy, including eribulin as sixth line among all chemotherapies received. Eribulin treatment achieved a fast response to all metastatic sites and decelerated the aggressive evolution of the second disease.

Original languageEnglish
Pages (from-to)51-54
Number of pages4
JournalFuture Oncology
Volume13
Issue number11s
DOIs
Publication statusPublished - May 1 2017

Keywords

  • aggressiveness
  • eribulin
  • metastatic breast cancer
  • second primary tumor

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Eribulin rapidly reduces the aggressiveness of second primary breast cancer: A case report'. Together they form a unique fingerprint.

Cite this